Table 1 Combined ID and IM efficacy studies.

OutcomeNumber of animals with outcome*
PolyC RNAgD2 mRNATrivalent mRNATrivalent protein
Clinical disease:
Death, genital lesions, or
generalized illness
25/251/100/440/20
P = 0.1852P = 1.0000
Subclinical infection
  Day 2 vaginal titers25/254/200/644/20
P = 0.0025P = 0.0025
  Day 4 vaginal titers25/253/200/644/20
P = 0.0120P = 0.0025
  HSV-2 DNA in DRG19/193/101/395/20
P = 0.0231P = 0.0143
Sterile immunity:
No clinical or subclinical
infection
0/2515/2063/6423/30
P = 0.0025P = 0.0012

*The primary end point is the comparison between trivalent mRNA-LNP and trivalent subunit protein. The secondary end point is the comparison between trivalent mRNA-LNP and gD2 mRNA-LNP. P values were calculated by two-tailed Fisher’s exact test.